Payment overview · 2025
General Payments
$1,129.59
48 reported records · 16 companies
Healthcare provider profile · identity verified
Raju Singla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FALL RIVER, MA · NPI 1043204407
Verified facts
What the public records show
CMS Open Payments records show Raju Singla, M.D. received $1,129.59 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.98 | 17.6% | 8 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $149.66 | 13.2% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.04 | 10.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.72 | 8.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.57 | 7.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.38 | 7.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.07 | 6.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.68 | 6.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.04 | 5.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.06 | 3.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.66 | 3.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.51 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.36 | 2.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.70 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.85 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.31 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,129.59 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $149.66 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $115.04 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.38 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.35 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.68 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $65.71 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.73 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 170 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
170 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 999 | 283 |
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 152 |
| Omeprazole | Omeprazole | 541 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 189 |
| Furosemide | Furosemide | 433 | 131 |
| Lisinopril | Lisinopril | 429 | 125 |
| Losartan Potassium | Losartan Potassium | 391 | 106 |
| Gabapentin | Gabapentin | 366 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 337 | 100 |
| Carvedilol | Carvedilol | 333 | 92 |
| Metformin Hcl | Metformin Hcl | 329 | 92 |
| Lorazepam | Lorazepam | 258 | 55 |
| Meloxicam | Meloxicam | 246 | 56 |
| Trazodone Hcl | Trazodone Hcl | 245 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 78 |
| Simvastatin | Simvastatin | 233 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 74 |
| Prednisone | Prednisone | 209 | 160 |
| Januvia | Sitagliptin Phosphate | 198 | 47 |
| Lovastatin | Lovastatin | 197 | 51 |
| Eliquis | Apixaban | 188 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 188 | 76 |
| Fenofibrate | Fenofibrate Nanocrystallized | 185 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 183 | 161 |
| Tramadol Hcl | Tramadol Hcl | 171 | 49 |
| Farxiga | Dapagliflozin Propanediol | 170 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 43 |
| Allopurinol | Allopurinol | 157 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 44 |
| Jardiance | Empagliflozin | 142 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 140 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 37 |
| Ezetimibe | Ezetimibe | 134 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 28 |
| Glimepiride | Glimepiride | 126 | 36 |
| Cefuroxime | Cefuroxime Axetil | 124 | 107 |
| Alprazolam | Alprazolam | 116 | 23 |
| Azithromycin | Azithromycin | 115 | 102 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 35 |
| Alendronate Sodium | Alendronate Sodium | 109 | 20 |
| Meclizine Hcl | Meclizine Hcl | 109 | 52 |
| Fenofibrate | Fenofibrate | 108 | 27 |
| Potassium Chloride | Potassium Chloride | 108 | 30 |
| Doxazosin Mesylate | Doxazosin Mesylate | 106 | 25 |
| Ibuprofen | Ibuprofen | 105 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 103 | 26 |
| Mirtazapine | Mirtazapine | 102 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 36 |
| Clonazepam | Clonazepam | 100 | 12 |
| Montelukast Sodium | Montelukast Sodium | 89 | 16 |
| Nystatin | Nystatin | 86 | 49 |
| Ozempic | Semaglutide | 86 | 13 |
| Trulicity | Dulaglutide | 83 | 13 |
| Celecoxib | Celecoxib | 81 | 18 |
| Clonidine Hcl | Clonidine Hcl | 80 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 29 |
| Metformin Hcl Er | Metformin Hcl | 78 | 24 |
| Sertraline Hcl | Sertraline Hcl | 78 | 22 |
| Famotidine | Famotidine | 72 | 22 |
| Diazepam | Diazepam | 64 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 53 |
| Atenolol | Atenolol | 62 | 20 |
| Tradjenta | Linagliptin | 62 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 11 |
| Repaglinide | Repaglinide | 57 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 15 |
| Hydrocortisone | Hydrocortisone | 51 | 36 |
| Spironolactone | Spironolactone | 51 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Bumetanide | Bumetanide | 44 | 16 |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 16 |
| Finasteride | Finasteride | 41 | 13 |
| Levofloxacin | Levofloxacin | 41 | 40 |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Irbesartan | Irbesartan | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | 11 |
| Amiloride Hcl | Amiloride Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 28 |
| Sucralfate | Sucralfate | 32 | 17 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Lactulose | Lactulose | 30 | 20 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Colchicine | Colchicine | 29 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 26 |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 26 |
| Glipizide | Glipizide | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 18 | 13 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,129.59 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AVYCAZ, DALVANCE, FARXIGA, GEMTESA, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Ohtuvayre, Ozempic, REXULTI, SHINGRIX, STRENSIQ, TEFLARO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error